Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296064 | 0.76 | CXCR4 (0.42) | SMN1; SMN2ALDH1A1KDM4ERAB9ACYP2A13 | |
| SCHEMBL14963331 | 0.74 | SSTR5 (0.85) | SSTR5 | |
| SCHEMBL13002963 | 0.73 | ALDH1A1 (0.67) | ARALDH1A1 | |
| SCHEMBL2089659 | 0.71 | PTGDR2 (0.48) | ARALDH1A1KDM4E | |
| SCHEMBL23315810 | 0.70 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1KDM4ERAB9ASLC2A1 | |
| SCHEMBL17014756 | 0.70 | AR (1.00) | ARSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL20462664 | 0.70 | PTGDR2 (0.48) | ALDH1A1KDM4E | |
| SCHEMBL12030408 | 0.70 | CNR1 (0.49) | ARSMN1; SMN2ALDH1A1KDM4ERAB9A | |
| SCHEMBL11714345 | 0.69 | NR4A2 (0.51) | SMN1; SMN2ALDH1A1KDM4ERAB9ASLC2A1 | |
| Hydrochloric Acid SCHEMBL2484635 | 0.69 | CNR1 (0.48) | ARALDH1A1KDM4ERAB9ASSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | AR 3534/4885SMN1; SMN2 3300/4885ALDH1A1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.